Rescue inhalers provide fast relief from asthma attacks and symptoms of chronic obstructive pulmonary disease by quickly delivering medication to the lungs. Containing short-acting beta2-agonists, rescue inhalers work within minutes to relax the muscles in the airways and improve breathing. The global rescue inhaler market is estimated to be valued at US$ 15.5 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing adoption of digital rescue inhalers is expected to significantly drive growth of the rescue inhaler market over the forecast period. Digital rescue inhalers are equipped with sensors to record usage data such as time and date of use. This data is transferred to a companion smart device application or online portal, allowing patients to better track their condition and medication use. As such, digital rescue inhalers help improve medication adherence and self-management of respiratory diseases. Their precise dosing also ensures prescribed medication is effectively delivered. With increasing preference for connected health solutions, digital rescue inhalers are poised to gain more prominence in the coming years.
Segment Analysis
The global rescue inhaler market is dominated by metered dose inhalers (MDI) sub segment. This is because MDIs provide effective and quick asthma/COPD symptom relief. MDIs account for more than 60% market share as they are portable, easy to use and affordable. Dry powder inhalers (DPI) sub segment is expected to witness fastest growth during forecast period owing to their advantages over MDIs such as ease of use, breath-actuation and no coordination of hand-breath needed.
Key Takeaways
The global rescue inhaler market is expected to witness high growth during the forecast period of 2023-2030. The market is anticipated to reach a value of US$ 15.5 Bn by 2023, expanding at a CAGR of 8.8% over the forecast years.
North America accounts for more than 35% of the global market share and is expected to remain the dominating region owing to high prevalence of asthma and COPD cases in the region. Asia Pacific rescue inhaler market is poised to witness fastest growth over the forecast period. Increasing pollution levels and changing lifestyle in developing countries of Asia Pacific such as China and India are driving the regional market.
Key players operating in the rescue inhaler market are GSK plc., Teva Pharmaceutical Industries Ltd., Cipla Inc., PARI Pharma GmbH, Lupin, AstraZeneca, Boehringer Ingelheim International GmbH., Novartis, Pfizer, Sunovion Pharmaceuticals, 3M, OMRON Healthcare Co., Ltd., Koninklijke Philips N.V., Schiller, and Teleflex Incorporated.
No comments:
Post a Comment